🔗 Share this article

The Nobel Prize in Physiology or Medicine has been granted for transformative discoveries that illuminate how the immune system targets harmful infections while sparing the body's own cells.

Three renowned researchers—Japan's Shimon Sakaguchi and American experts Mary Brunkow and Fred Ramsdell—share this accolade.

Their work identified unique "sentinels" within the defense system that remove rogue immune cells capable of attacking the organism.

These discoveries are now paving the way for innovative therapies for autoimmune diseases and cancer.

These winners will divide a monetary award worth 11 million Swedish kronor.

Decisive Findings

"The work has been decisive for comprehending how the body's defenses operates and the reason we don't all develop serious self-attack conditions," commented the chair of the award panel.

This team's research explain a core question: In what way does the defense system defend us from countless invaders while leaving our own tissues unharmed?

Our body's protection system employs immune cells that scan for indicators of infection, including pathogens and germs it has not met before.

These cells utilize detectors—called recognition units—that are generated by chance in countless variations.

This provides the defense network the ability to combat a wide array of threats, but the randomness of the process inevitably produces immune cells that can target the host.

Protectors of the Body

Researchers earlier understood that a portion of these problematic defense cells were destroyed in the immune organ—where immune cells mature.

This year's Nobel Prize honors the discovery of T-reg cells—described as the immune system's "peacekeepers"—which travel through the body to disarm any defenders that assault the body's own tissues.

It is known that this mechanism malfunctions in autoimmune diseases such as juvenile diabetes, MS, and rheumatoid arthritis.

The Nobel panel stated, "These discoveries have established a novel area of investigation and spurred the development of innovative therapies, for example for cancer and immune disorders."

In malignancies, regulatory T-cells prevent the body from fighting the tumor, so research are aimed at lowering their quantity.

In autoimmune diseases, trials are testing increasing regulatory T-cells so the organism is no longer under attack. A comparable method could also be useful in reducing the risks of transplanted organ rejection.

Innovative Experiments

Professor Shimon Sakaguchi, of a Japanese institution, conducted tests on mice that had their thymus removed, leading to self-attack conditions.

He demonstrated that introducing defense cells from healthy mice could stop the illness—implying there was a system for preventing defenders from harming the body.

Dr. Brunkow, from the a research center in a US city, and Dr. Ramsdell, now at a biotech firm in San Francisco, were studying an genetic immune disorder in rodents and humans that resulted in the identification of a gene vital for the way T-regs operate.

"Their pioneering research has revealed how the body's defenses is kept in check by T-reg cells, stopping it from mistakenly attacking the body's own tissues," commented a prominent physiology expert.

"This work is a striking illustration of how fundamental biological research can have broad implications for human health."